Carvedilol therapy improved cardiac function and increased free fatty acid metabolism in a patient with dilated cardiomyopathy and type I CD36 deficiency.
Case Report (n=1)
A 27-year-old man diagnosed as having dilated cardiomyopathy (DCM) without myocardial accumulation of 123I-beta-methyl-iodophenylpentadecanoic acid, and he was found to have type I CD36 deficiency. This abnormality of cardiac free fatty acid metabolism was also confirmed by other methods: 18F-fluoro-2-deoxyglucose positron emission tomography, measurements of myocardial respiratory quotient and cardiac fatty acid uptake. Although the type I CD36 deficiency was reconfirmed after 3 months, the abnormal free fatty acid metabolism improved after carvedilol therapy and was accompanied by improved cardiac function. Apart from a cause-and-effect relationship, carvedilol can improve cardiac function and increase free fatty acid metabolism in patients with both DCM and CD36 deficiency.
Hirooka et al. (Sat,) conducted a case report in Dilated cardiomyopathy with type I CD36 deficiency (n=1). Carvedilol was evaluated on Cardiac function and free fatty acid metabolism. Carvedilol therapy improved cardiac function and increased free fatty acid metabolism in a patient with dilated cardiomyopathy and type I CD36 deficiency.